CliffBio
small molecule

MITOSOL

MITOMYCIN

Loss of exclusivityMay 2029latest FDA-listed patent expiry
CompanyGlaukos →View the full company profile on CliffBio

Drug detail

Brand nameMITOSOL
Active ingredientMITOMYCIN
Strength0.2MG/VIAL
Dosage formFOR SOLUTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalFebruary 2012
Marketing statusRX

Listed patents

PatentExpiresType
9649428May 2029use U-2095
7806265February 2029product
9539241January 2028substance, product
8186511July 2026product
9205075July 2026product

More from Glaukos

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MITOSOL patent cliff — loss of exclusivity May 2029 | CliffBio